[go: up one dir, main page]

WO2000078330A3 - Adenosine diphosphatase and activators thereof and their medical uses - Google Patents

Adenosine diphosphatase and activators thereof and their medical uses Download PDF

Info

Publication number
WO2000078330A3
WO2000078330A3 PCT/GB2000/002333 GB0002333W WO0078330A3 WO 2000078330 A3 WO2000078330 A3 WO 2000078330A3 GB 0002333 W GB0002333 W GB 0002333W WO 0078330 A3 WO0078330 A3 WO 0078330A3
Authority
WO
WIPO (PCT)
Prior art keywords
activators
adpase
medical uses
adenosine diphosphatase
ipgs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/002333
Other languages
French (fr)
Other versions
WO2000078330A2 (en
Inventor
Patricia Mclean
Leslie Greenbaum
Thomas William Rademacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rademacher Group Ltd
Original Assignee
Rademacher Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rademacher Group Ltd filed Critical Rademacher Group Ltd
Priority to CA002368099A priority Critical patent/CA2368099A1/en
Priority to JP2001504393A priority patent/JP2003502381A/en
Priority to AU55472/00A priority patent/AU5547200A/en
Priority to EP00940550A priority patent/EP1185295A2/en
Publication of WO2000078330A2 publication Critical patent/WO2000078330A2/en
Publication of WO2000078330A3 publication Critical patent/WO2000078330A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The present invention relates to materials and methods for the diagnosis and treatment of pre-eclampsia and related conditions characterised by platelet aggregation. In particular it relates to the use of adenosine diphosphatase (ADPase) and activators of ADPase for the treatment of pre-eclampsia, in order to overcome the inhibition of ADPase by inositol phosphoglycans (IPGs). Also provided is a method for screening for compounds with ADPase-stimulatory activity in the presence or absence of IPGs.
PCT/GB2000/002333 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses Ceased WO2000078330A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002368099A CA2368099A1 (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses
JP2001504393A JP2003502381A (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof, and their medical uses
AU55472/00A AU5547200A (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses
EP00940550A EP1185295A2 (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9914326.5 1999-06-18
GBGB9914326.5A GB9914326D0 (en) 1999-06-18 1999-06-18 Materials and methods relating to the diagnosis and treatment of pre-eclampsia

Publications (2)

Publication Number Publication Date
WO2000078330A2 WO2000078330A2 (en) 2000-12-28
WO2000078330A3 true WO2000078330A3 (en) 2001-05-25

Family

ID=10855663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002333 Ceased WO2000078330A2 (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses

Country Status (6)

Country Link
EP (1) EP1185295A2 (en)
JP (1) JP2003502381A (en)
AU (1) AU5547200A (en)
CA (1) CA2368099A1 (en)
GB (1) GB9914326D0 (en)
WO (1) WO2000078330A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053715A2 (en) * 2001-01-02 2002-07-11 Bayer Aktiengesellschaft Nucleoside diphosphate hydrolase
ES2718905T3 (en) * 2012-04-24 2019-07-05 Siemens Healthcare Diagnostics Inc Preeclampsia test methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030532A1 (en) * 1995-03-24 1996-10-03 Novartis Ag Gene therapy for transplantation and inflammatory or thrombotic conditions
WO1998010791A1 (en) * 1996-09-11 1998-03-19 Rademacher Group Limited Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
WO2000023094A2 (en) * 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030532A1 (en) * 1995-03-24 1996-10-03 Novartis Ag Gene therapy for transplantation and inflammatory or thrombotic conditions
WO1998010791A1 (en) * 1996-09-11 1998-03-19 Rademacher Group Limited Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
WO2000023094A2 (en) * 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAKKER W W ET AL: "Platelets and ectonucleotidases.", PLATELETS, vol. 5, no. 3, June 1994 (1994-06-01), pages 121 - 129, XP000971341 *
GAYLE R B III ET AL: "Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39", JOURNAL OF CLINICAL INVESTIGATION, vol. 101, no. 9, 1 May 1998 (1998-05-01), pages 1851 - 1859, XP002136365 *
MATSUBARA ET AL: "Ultrastructural localization and cytochemical characteristics of human placental ADP-degrading activity in normal and preeclamptic pregnancy", TROPHOBLAST RESEARCH, vol. 9, 1997, pages 121 - 129, XP000971398 *

Also Published As

Publication number Publication date
AU5547200A (en) 2001-01-09
CA2368099A1 (en) 2000-12-28
WO2000078330A2 (en) 2000-12-28
GB9914326D0 (en) 1999-08-18
JP2003502381A (en) 2003-01-21
EP1185295A2 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
Lee et al. Production and hydrolysis of cyclic ADP-ribose at the outer surface of human erythrocytes
Sburlati et al. Chitin synthetase 2, a presumptive participant in septum formation in Saccharomyces cerevisiae.
AU9058091A (en) Preparation of nucleic acid samples
WO2007127936A3 (en) Methods and compositions for antibody therapy
WO2007010305A3 (en) Surgical membrane
WO1999019290A3 (en) Lactic acid processing; methods; arrangements; and, products
WO1997040141A3 (en) Isolation of enzymes
FR2697801B1 (en) Process for the logistical monitoring of handling parts and / or their content, as well as the part itself.
ATE378402T1 (en) DEVICE AND METHOD FOR PRODUCING AUTOLOGUE THROMBIN SERUM
EP0364690A3 (en) The alpha-subunit of the mac-1 leukocyte adhesion receptor
CA2251624A1 (en) Method for removal of psoralens from biological fluids
AU4310297A (en) Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
EP0606187A3 (en) Composite reactive articles for the determination of cyanide.
BR8702649A (en) BIOCIDAL COMPOSITION, PROCESS FOR INHIBITING THE GROWTH OF MICROORGANISMS, MEDIUM, LEATHER OR WOOD, COMPOUND AND FERRO COMPLEX
WO2000078330A3 (en) Adenosine diphosphatase and activators thereof and their medical uses
CA2314150A1 (en) Recovery of functional human leukocytes from recycled filters
FR2817349B1 (en) NEW METHOD FOR SCREENING MODULATORS OF THE BACTERIAL TRANSCRIPTION
HUP0103754A3 (en) Crystal of diuridine tetraphosphate or salt thereof and method for preparing the same, and method for producing said compound
EP1088897A8 (en) Method for differentiating microorganisms in a sample
AU5651186A (en) Method of production of magnetized seed, seedlings or the like
WO2004050102A8 (en) Methods for preparing a solid-fibrin web
AU542081B2 (en) Hardening of ferrous alloys by coating with carbo-nitride of vanadiam, niobiam or tantalum
WO2022082178A3 (en) Methods for treating and monitoring frontotemporal dementia
HU9301316D0 (en) Method for application of prothrombin fragments
WO2005079531A3 (en) Method and system for eluting cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000940550

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2368099

Country of ref document: CA

Ref country code: CA

Ref document number: 2368099

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 504393

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 55472/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000940550

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000940550

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642